Novo A/S (investor - Corporate Investor)

See something wrong or missing? Let us know
Offices:
Hellerup
Key People:
Søren Carlsen
Average round investment:
21.35M USD

Novo A/S is a private limited liability company fully owned by the Novo Nordisk Foundation.

Besides being the major shareholder in the Novo Group companies, Novo A/S provides seed (Novo Seeds) and venture capital (Novo Ventures) to development stage companies and takes significant ownership positions in well-established companies, within life science, as well as manages a broad portfolio of financial assets.

We tracked 13 Nordic investments.

You need an account to access this feature. Login or create one from here. (it takes 20 seconds)

Novo A/S investments breakdown analysis:

You need an account to access this feature. Login or create one from here. (it takes 20 seconds)

Novo A/S mostly invests with:

You need an account to access this feature. Login or create one from here. (it takes 20 seconds)

Investors with similar profile to Novo A/S:

InvestorCriteria
Denmark Novo Seeds
78%
  • Range for average deal size: 10M - 20M USD
  • Similar verticals: Biotech, Health services, Pharma
  • Similar business models: B2B
  • Common investees countries: Denmark
  • Average number of deals per year: 3.2
  • Active last 12 months: Yes
Denmark Lundbeckfond Ventures
72%
  • Range for average deal size: 20M - 50M USD
  • Similar verticals: Biotech, Health services, Pharma
  • Similar business models: B2B
  • Common investees countries: Denmark
  • Average number of deals per year: 1.6
Denmark Sunstone Life Science Ventures
70%
  • Range for average deal size: 20M - 50M USD
  • Similar verticals: Biotech, Health services, Pharma
  • Similar business models: B2B
  • Common investees countries: Denmark
  • Average number of deals per year: 1.3
Netherlands INKEF Capital
64%
  • Range for average deal size: 10M - 20M USD
  • Similar verticals: Biotech, Health services
  • Similar business models: B2B
  • Average number of deals per year: 2.6
  • Active last 12 months: Yes
Seventure Partners
63%
  • Range for average deal size: 20M - 50M USD
  • Similar verticals: Biotech, Health services
  • Similar business models: B2B
  • Common investees countries: Denmark
  • Average number of deals per year: 1.3
  • Active last 12 months: Yes
Sofinnova Partners
60%
  • Range for average deal size: 20M - 50M USD
  • Similar verticals: Biotech, Health services
  • Similar business models: B2B
  • Common investees countries: Denmark
  • Average number of deals per year: 1.2
United States e.ventures
57%
  • Range for average deal size: 10M - 20M USD
  • Similar verticals: Health services
  • Similar business models: B2B
  • Common investees countries: Denmark
  • Average number of deals per year: 2.4
  • Active last 12 months: Yes
Germany Project A Ventures
57%
  • Range for average deal size: 20M - 50M USD
  • Similar verticals: Health services
  • Similar business models: B2B
  • Common investees countries: Denmark
  • Average number of deals per year: 1.8
  • Active last 12 months: Yes
Sweden HealthCap
56%
  • Range for average deal size: 20M - 50M USD
  • Similar verticals: Biotech, Health services
  • Similar business models: B2B
  • Average number of deals per year: 1.4
France Kurma Life Science Partners
56%
  • Range for average deal size: 10M - 20M USD
  • Similar verticals: Biotech, Pharma
  • Similar business models: B2B
  • Average number of deals per year: 1

News about Novo A/S

You need an account to access this feature. Login or create one from here. (it takes 20 seconds)